Free Trial

Nurix Therapeutics Q1 2024 Earnings Report

Nurix Therapeutics logo
$14.19 -1.26 (-8.16%)
As of 03/3/2025 04:00 PM Eastern

Nurix Therapeutics EPS Results

Actual EPS
-$0.76
Consensus EPS
-$0.80
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Nurix Therapeutics Revenue Results

Actual Revenue
$16.59 million
Expected Revenue
$14.58 million
Beat/Miss
Beat by +$2.01 million
YoY Revenue Growth
N/A

Nurix Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A

Nurix Therapeutics Earnings Headlines

Nurix Therapeutics: A Story To Monitor
Your Wealth is Under Attack
Please don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your free gift, and see how Trump's victory could spark major gains for gold.
Nurix Therapeutics price target raised to $17 from $16 at Morgan Stanley
See More Nurix Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nurix Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nurix Therapeutics and other key companies, straight to your email.

About Nurix Therapeutics

Nurix Therapeutics (NASDAQ:NRIX), a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

View Nurix Therapeutics Profile

More Earnings Resources from MarketBeat